Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22797936 | 0.89 | SLC6A4 (0.41) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL22449324 | 0.86 | SLC6A2 (0.39) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL22797956 | 0.86 | TACR1 (0.39) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL22797790 | 0.85 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL22797911 | 0.85 | SLC6A2 (0.44) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL27176078 | 0.83 | TACR1 (0.37) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL3006964 | 0.83 | KDM4E (0.38) | TACR1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL22797851 | 0.81 | TACR1 (0.36) | TACR1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL20596706 | 0.81 | SLC6A4 (0.35) | TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22797904 | 0.80 | TACR1 (0.35) | TACR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167272-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167272-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | TACR1 20/4885SLC6A2 591/4885SLC6A4 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.